Clinical trial
A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in…
NCT00199290 · Kaken Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00199290 |
|---|---|
| Title | A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan |
| Official title | A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan |
| Lead sponsor | Kaken Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Periodontitis |
| Intervention type | Drug |
| Interventions | Trafermin (genetical recombination) |
| Enrollment | 267 |
| Start date | Aug 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Feb 5, 2008 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: